Diamonds and Dogs


Another drug stock shooting higher. GW Pharmaceuticals plc (GWPH) is jumping 14% to a new 52 week high after reporting positive Phase 3 clinical trial results for their drug to treat seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. In this trial, Epidiolex, when added to the patient's current treatment, achieved the primary endpoint for both dose levels with high statistical significance. This trial follows the announcement in June 2016 of positive results in the first pivotal Phase 3 trial of Epidiolex for the treatment of seizures associated with LGS, and the March 2016 announcement of positive results in the treatment of seizures associated with Dravet syndrome. Good year for GW Pharma's patients and shareholders.


Merger Monday not helping the CBOE. CBOE Holdings (CBOE) is down 4% after agreeing to acquire rival exchange operator Bats Global for US $3.2 billion. The transaction, which has already been approved by both companies' boards, reflects CBOE's ambition to expand in Europe and gain a bigger foothold in the fast-growing market for exchange-traded funds. The buyout represents a 70% gain for investors that participated in Bats' IPO just five months ago. Bats shares closed 20% higher last Friday after news of the acquisition circulated, while CBOE stock was up just over 1%.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.